I'm interested in your thoughts on this. I would expect a successful Rett trial to be a validation of the overall approach that 2-73 is using to treat disease. As such I'd expect it to be looked upon as increasing the apparent odds of success of the other trials.
So, I'd expect an out sized response to a Rett success.
You apparently see the situation differently. Would you mind sharing you perspective on this?
So, we will likely be diluted, it's just a question of how much.
After the initial hit on the stock on Friday and next few days wears off we could resume higher. The problem is that the way this S-3 is constructed every time Anavex goes to tap to shelf a new prospectus is filed and the stock will likely get hit again depending up what is going on. Absent any positive reasons for the raise the stock will get hit again. The cycle repeats until there is positive news associated with any raise.